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The diagnosis and management of asthma in young children is difficult, since there are many different wheezy phenotypes with varying underlying 
aetiologies and outcomes. This review discusses the different approaches to managing young children with wheezy illnesses presented in recently 
published global guidelines. Four major guidelines published since 2007 are considered. Helpful approaches are presented to assist the clinician to 
decide whether a clinical diagnosis of asthma can, or should be made in a young child with a recurrent wheezy illness and which treatments would 
be appropriate, dependent on risk factors, age of presentation, response to initial treatment and safety considerations. Each of the guidelines pro-
vide useful information for clinicians assessing young children with recurrent wheezy illnesses. There are differences in classification of the disease 
and treatment protocols. Although a firm diagnosis of asthma may only be made retrospectively in some cases and there are several effective guide-
lines to initiating treatment. Consistent review of the need for ongoing treatment with a particular pharmacological modality is essential, since 
many children with recurrent wheezing in infancy go into spontaneous remission. It is probable that newer biomarkers of airway inflammation will 
assist the clinician as to when to initiate and when to continue pharmacological treatment in the future.
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INTRODUCTION
Asthma is a leading cause of chronic disease in children glob-
ally. Since the international study of asthma and allergies in 
childhood (ISAAC) epidemiological research programme was 
established in 1991, a phase three study in 2002-2003 in 193,404 
children aged 6-7 years from 66 centres in 37 countries, con-
ducted 7 years after the phase 1 study showed a marked change 
in disease prevalence, with increases being twice as common 
as decreases in the 6-7 year old age group than in the 13-14 year 
old comparator group of children.
1 There are no global epide-
miological studies of asthma or wheezy illnesses in children 
under 5 years of age. Reasons for this include difficulty in mak-
ing a confident diagnosis, a lack of objective diagnostic criteria, 
logistical and ethical problems and the variability of the expres-
sion of wheezy illnesses in children 5 years and under.
Asthma guidelines have been developed during the past 17 
years to increase the awareness of asthma among health pro-
fessionals, to improve asthma management, to evaluate pub-
lished reports on asthma and to promote international collabo-
ration in asthma research. The first international guidelines 
were formulated by the National Heart Lung and Blood Insti-
tute (NHLBI) in the USA in 1991
2 and this expert panel report 
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was updated in 1997
3 and reviewed by Jahad
4 in a meta analysis 
and updated in 2003
5 and finally published in 2008 as an Expert 
Panel Report 3 (EPR-3).
6
Currently there are 4 major guidelines which address the 
management of asthma in young children. The EPR3 of the Na-
tional Asthma Education Programme (NAEPP),
6 the PRAC-
TALL Consensus Report published by the European Academy 
of Asthma and Allergy in 2008,
7 an Evidence Based Approach 
compiled by the European Respiratory Society task force, pub-
lished in the European Respiratory Journal in 2008
8 and most 
recently the Global Initiative (GINA) published new evidence 
based guidelines for the diagnosis and management of asthma 
in children 5 years and younger in 2009 (www.ginasthma.org).
9
The reason for having at least 4 new “global” guidelines pub-
lished in the past 2 years to address the management of asthma 
in young children stems from lack of agreement on the diagno-
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sis of asthma in young children, paucity of published studies on 
different treatments for asthma and wheezy illnesses in the un-
der 5’s, a lack of published biopsy studies on the pathology of 
wheezy illnesses in young children. There are also differences 
in different regions of the world in resources for treatment, 
modes of communication and availability of different treat-
ments.
Some have considered that with a lack of hard evidence, as 
would be obtained by large double blind placebo controlled 
studies, a consensus approach based on evidence in older chil-
dren and clinical experience is more appropriate.
7 Even when 
stricter criteria for recommendations are upheld according to 
published evidence only,
8 the dilemma of whether asthma can 
be diagnosed with confidence in the under five aged group aris-
es.
9 It is more difficult to formulate guidelines for asthma in the 
younger children firstly because the diagnosis for asthma may 
not be sure and children express different patterns of wheezy 
illnesses, but also because asthma itself is a “syndrome” com-
posed of heterogeneous diseases.
10
It is thus believed that asthma is unlikely to be a single disease, 
but rather a series of complex overlapping individual diseases 
or phenotypes, each defined by its unique interaction between 
genetic and environmental factors. These conditions include 
syndromes exacerbated by exposure to allergens, and aspirin 
exacerbated, or non-allergic factors, along with syndromes best 
distinguished by their pathological findings (neutrophilic, eo-
sinophilic, pauci granulocytic), their response to therapy (corti-
costeroid resistant, or leukotriene receptor antagonist sensitive) 
and natural history (intermittent or persistent or remittent) de-
pending on the development of airway remodelling and other 
factors such as exposure and genotype.
It is against this background of a clear heterogeneity in the 
asthma phenotypes encountered in older children and adults, 
that the literature is deplete on information on the natural his-
tory of the disease, which starts in infancy. It is not known which 
childhood phenotypes develop into any of the defined adult 
type asthma phenotypes.
Thus in developing guidelines it would appear that the cur-
rent objectives and goals have been to recommend treatments, 
which are effective for “current control” of the disease, rather 
than treatments which modify the natural history of the dis-
ease. Other than “allergen specific immunotherapy” for asth-
ma, caused by and precipitated by a single allergen, which in it-
self is rare, even in children, there are no other treatments 
known to modify the natural history of the disease.
An important consideration in the development of guidelines 
is that the ISAAC data
1 clearly show that the increases noted in 
childhood asthma have not been confined to the developed 
countries, but that asthma also poses a huge burden to the un-
derdeveloped world, where resources are scarce and there is 
competition for resources to treat other diseases such as TB, 
AIDS, malnutrition, malaria and other infectious diseases.
The applicability of any guideline for asthma rests on access to 
medications recommended in such guidelines. Khalied et al.
11 
have stressed that access to inhaled corticosteroids is they key 
to improving quality care for asthma in developing countries. 
In developed countries a high cost of essential medications can 
be a major obstacle for patients who need such treatment and 
in many developing countries many essential drugs are un-
available for asthma treatment and literacy and language barri-
ers are significant obstacles to implementation of guidelines.
12
It is difficult to apply current new guidelines for the manage-
ment of children under 5 years, if the only asthma medications 
on the World Health Organization essential drug list includes 
Beclomethazone, Epinephrine, Ipratropium bromide and Sal-
butamol (WHO Essential Drug List, March 2007). Even when 
optimal treatment available, only 30-40% of patients are totally 
controlled.
13
Management goals for childhood asthma are fairly consistent 
between the different guidelines. The aims are for a “normal 
life” free of any symptoms (e.g., cough, wheeze and breathless-
ness), the ability to have a restful sleep, to grow and develop 
normally, to attend school or preschool regularly and partici-
pate in all school activities including sports, to minimise the 
number of attacks of acute asthma, to avoid hospitalisation and 
to avoid medication related side effects.
The impact of the disease needs to be weighed against the 
possible impact of the therapy. In the case of asthma treatment 
for children there are issues which are also extremely important 
to the parents, such as normal appetite, good academic perfor-
mance at school, social development and lack of irritability or 
disruption of family life. Quality of life is difficult to assess in 
young children and symptom scores may not correlate well 
with quality of life ratings. Quality of life may be also influenced 
by differences in society and cultural needs.
Treatment of the young child also differs from that of the old-
er child because in addition to lung functions being difficult 
under the age of 5, there are challenges to adequate delivery of 
inhaled drugs, safety issues and ethical issues. Furthermore, 
there are dosing issues. For many drugs used in young children 
careful dose ranging studies have not been conducted and dos-
ing is extrapolated from adult doses.
14 This dilemma results 
from the difficulties experienced in conducting necessary dou-
ble bind placebo controlled studies of asthma medications at 
different ages in young children bearing in mind the rights of 
the child, the fact that children are not “mini adults” , primary 
and secondary end points of paediatric and infant studies are 
not always fully objective due to “second party” reporting of 
outcomes by parents and caregivers and the assessment of on-
going inflammation is difficult. To address the deficiency in 
paediatric studies the FDA modernization and best pharma-
ceuticals for children’s act has been promulgated, the Europe-
an Medicines Evaluation Agency has published a “note for 
guidance on clinical investigation for medical products in the Allergy Asthma Immunol Res. 2010 January;2(1):1-13.  doi: 10.4168/aair.2010.2.1.1
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population” and the Therapeutics Goods Administration (TGA) 
of Australia has given priority to paediatric submissions to en-
courage industry to study all new products in children.
In practice this will involve studies in which the dosages are 
weight related, patients are clearly phenotyped according to the 
onset and type of wheezy illness, differences in the pharmaco-
kinetics of the drug are studied and measurable effects on in-
flammation are also considered (e.g., PD20, eNo, urinary leu-
kotrienes, sputum eosinophilic cationic protein and other im-
munological markers), in addition to variables such as airway 
hyperresponsiveness, growth, height, quality of life and disease 
modification.
Bearing in mind the variability of the triggers of wheeze in 
young children (viruses, allergens, irritants, emotional factors 
exercise), it is thus difficult to standardise all these variables to 
study the effects of a particular drug on a particular outcome, in 
a sufficiently large number of children, including a placebo 
arm. Furthermore longer studies may be necessary to study 
whether a particular drug has a disease modifying capability, 
bearing in mind the tendency of wheezing illnesses to sponta-
neously remit in a significant number of young children.
It is important to stress that a number of young children pre-
senting with wheeze may not have asthma. The younger the 
child, the greater the possibility of an alternative diagnosis, e.g., 
gastroesophageal reflux, cystic fibrosis, aspiration syndrome, 
immune deficiency, congenital heart disease and bronchopul-
monary dysplasia.
Furthermore there are a number of risk factors which increase 
the likelihood of the development of asthma in young children 
in addition to genetic factors. Risk factors for asthma attacks in-
clude exercise, exposure to specific allergens, viral infections, 
tobacco smoke, certain foods and food additives such as sul-
phur dioxide and emotional factors. In addition the choice of 
treatment will be influenced by the history which should con-
sider the frequency of previous attacks, the severity of previous 
attacks, previous hospitalisation, repeated use of oral steroids 
such as prednisolone, the level of treatment previously neces-
sary to obtain “control” , attendance at a crèche, concurrent rhi-
nitis and rate of response to treatment.
THE NAEPP EP3 GUIDELINES
The first of the “recently published” guideline for the manage-
ment of asthma in young children is the EP3 NAEPP report pub-
lished in 2007.
6 These guidelines point out that 50-80 percent of 
children who have asthma, develop symptoms before their fifth 
birthdays, but because the disease is frequently under diag-
nosed many young children do not receive adequate therapy. 
On the other hand, since not all wheeze is caused by asthma, 
one should exert caution to avoid infants and younger children 
receiving inappropriate prolonged asthma therapy.
The diagnosis of asthma is difficult. If one considers the pres-
ence of airway inflammation to be central to the diagnosis of 
asthma, confirmation of this is not usually possible in younger 
children, using available clinical tools in practice. However, ele-
vations in both inflammatory cells and mediators have been 
demonstrated in broncho alveolar large specimens obtained 
from preschool children who have recurrent wheezing.
15 Thus in 
children 0-4 years of age, in some cases a therapeutic trial with 
medications may also aid in confirming a diagnosis, whereas in 
children 5-11 years one has the advantage of a preceding history 
and also simple lung function tests for reversibility, to aid the di-
agnosis.
In the under fives the most common cause of asthma symp-
toms is viral respiratory infection. Some remit in the preschool 
years and others persist throughout childhood. It appears that 
children under 3 years of age who have more than four epi-
sodes of wheezing in the past year, affecting sleep are signifi-
cantly more likely to develop persistent asthma after the age of 
5 years, particularly if they have a parental history of asthma, a 
physician diagnosis of atopic dermatitis, sensitization to aeroal-
lergens, evidence of food sensitisation, a greater than 4 percent 
peripheral blood eosinophilia or wheezing apart from colds.
The Expert Panel 3 concluded that early intervention with in-
haled corticosteroids continuously
16 or intermittently
17 did not 
alter the underlying severity or progression of the disease and 
that inhaled corticosteroids should be used to control asthma 
symptoms and improve the child’s quality of life, but not for the 
purpose of changing the natural history of the disease (Evi-
dence A).
It appears that while the disease may in fact progress during 
the first 5 years of life, the recent childhood management pro-
gramme study (CAMP) indicated that children aged 5-12 years 
who have mild or moderate persistent asthma, do not on aver-
age have a progressive decline in lung function. In the subset of 
these who experienced progressive reductions in lung growth 
compared to predicted measures, this was not prevented by in-
haled steroids.
18
Observational prospective data from Martinez et al. suggests 
that most loss of lung function occurs during the first 3-5 years 
of life.
19 Although this is the case, the studies by Guilbert et al.
16 
in 2006 showed that ICS clearly reduced the symptom burden 
and frequency of exacerbations when administered daily for 2 
years, but did not prevent the reappearance of symptoms in the 
year of follow up after discontinuing therapy.
The EP3 guidelines recommend a regular follow up of those 
children who have moderate a persistent asthma to assess im-
pairment and risk domains for the development of progressive 
disease. These include requirements for intermittent short act-
ing b2 stimulants, exacerbations requiring systemic steroids, ur-
gent care visits and if possible pulmonary function measures.
The concept of “reducing impairment” refers to the mainte-
nance of current well-being of the child as evidenced by reduc-
tion of symptoms, maintaining near normal pulmonary func-Allergy Asthma Immunol Res. 2010 January;2(1):1-13.  doi: 10.4168/aair.2010.2.1.1
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tion meeting family needs and expectations and maintaining 
current normal activity levels, exercise and school attendance.
The concept of “reducing risk” outlined by the EP-3 attempts 
to prevent recurrent exacerbations of asthma and the need for 
emergency care visits or hospitalisations, prevention of pro-
gressive loss of lung function and minimization of adverse 
events. It is recommended that both domains are considered as 
both affect quality of life, but that these domains respond dif-
ferently to treatment. Thus, low dose steroids may reduce im-
pairment (symptoms, SABA use and lung function), but does 
not reduce exacerbations requiring corticosteroids.
While most of the new guidelines emphasise the role of the 
clinician in assessing and maintaining “control” of asthma in 
an established treatment regime, when young patients are seen 
for their first episode of wheezing and factors like severity, age 
of onset, family history and the presence of other risk factors 
will influence the clinician’s decision regarding appropriate 
therapy.
The EPR-3 recommends that “impairment” and exacerba-
tions may be reduced by regular controller treatment in chil-
dren who have four or more episodes of wheezing in the past 
year persisting for more than a day, plus a parental history of 
asthma, atopic dermatitis, sensitization to aeroallergens, a >4% 
peripheral eosinophilia and wheezing apart from colds. The 
guideline recommends a stepwise approach to treatment start-
ing with low dose inhaled corticosteroids, or Montelukast.
Doses for most inhaled steroids in the 0-4 year’s old group are 
not published. The daily dose for Budesonide inhalation sus-
pension is recommended at 0.25-0.5 mg and of Fluticasone at 
176 µg/day, with no specific doses recommended for Budeso-
nide, Beclomethazone, Fluinisolide, Mometasone or Triamcin-
olone for the under five year old asthmatics. Daily doses for the 
5-11 year old asthmatics are 80-160 µg Beclomethazone, 180-
400 µg Budesonide, 500-750 µg Fluinisolide, 160 µg Fluini  solide 
HFA, 80-176 mg Fluticazone HFA MDI, 100-200 µg Flu  ticasone 
DPI and 300-600 µg Triamcinolone.
The above doses are regarded as low daily doses and can be 
stepped up (usually doubled) to a medium dose in children 5- 
11 years and quadrupled as a high daily dose in severe child-
hood asthmatics. In the absence of published studies the EP3 
guidelines are extremely cautious in recommending specific 
doses of inhaled steroid for the 0-4 year old asthmatics. Monte-
lukast 4 mg is recommended for under 5 year olds and 5 mg 
from 6-11 year olds (Evidence A).
In addition, long term controller therapy with inhaled cortico-
steroid should be considered to reduce impairment in infants 
and young children who consistently require treatment more 
than 2 days per week for more than 4 weeks (Evidence D), for 
reducing exacerbations requiring systemic corticosteroids 
within a 6 month period (Evidence D) or during a period of a 
previously documented risk for a child (e.g., Winter, Spring, 
specific exposure) (Evidence D), but that discontinuation must 
be considered when the period of risk has passed.
Once the child is on long term treatment with daily preventers 
adjustments may be made by assessing both the impairment 
and risk domains. These must be complemented by adequate 
education of the child and care giver, with particular attention 
to the level of adherence, to assess whether treatment should 
be stepped up or down.
Consideration of referral to a specialist is essential if there are 
difficulties in controlling the asthma, children who require step 
3 or higher or if an exacerbation requires hospitalisation. A spe-
cialist would also assess a possible role for immunotherapy and 
consider the role of allergy.
Furthermore the EP3 panel is of the opinion that ICS may be 
reduced by 25-50% every 3 months to the lowest possible dose 
to maintain control (Evidence D). Reduction should be gradual 
and since guidelines for stepping down treatment have not 
been validated, and clinical judgement of the individuals’ re-
sponse to therapy is very important. ICS at low doses for ex-
tended periods are safe. The potential for adverse events on 
medium to high dose ICS is usually limited to a small reduction 
in growth velocity of approximately 1 cm in the first year of 
treatment which is not progressive over time and can be mea-
sured by a stadiometer.
20, 21
In children who are required to receive high dose corticoste-
roids, age appropriate dietary intake of calcium and vitamin D 
should be reviewed with the child’s care givers (Evidence D) 
and slit lamp eye examination and bone densitometry should 
be considered (Evidence D).
In the USA only the following are approved by the FDA for 
young children under 4 years: ICS Budesonide nebuliser solu-
tion (1-8 years of age), ICS Fluticasone DPI (4 years and older), 
Salmeterol used in combination with Fluticasone for children 4 
years and older, Montelukast 4 mg as a chewable tablet 2-6 years 
of age and as granules down to 1 year of age. Cromolyn nebulis-
er is approved for children ≥2 years of age. Appropriate delivery 
devices are essential. Children under 4 should use a MDI with a 
valved holding chamber or nebuliser with a face mask. The step-
wise approach to treatment recommended by the EP3 is given 
in Fig. 1.
6
In this guideline both LABA or Montelukast is given as add on 
in the 0-4 years of age which differs from some of the other 
guidelines.
Theophylline is not recommended for children under 5 years. 
Montelukast is recommended as a trial in children 2 years or 
older, in situations where inhaled medication delivery is subop-
timal due to poor technique. There is no data on the use of long 
acting b2 agonist under the age of 4 years. Montelukast may also 
be considered as add on therapy. Recommendations for treat-
ment according to components of severity, impairment and risk 
according to the NAEPP EP3 guidelines are summarised in Fig. 
2 and a figure for assessment of control and adjusting therapy 
for children 0-4 years of age is given in Fig. 3. The EP3 guidelines Allergy Asthma Immunol Res. 2010 January;2(1):1-13.  doi: 10.4168/aair.2010.2.1.1
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are the most detailed for children under 5 years, but not all of 
the recommended steps for treatment are evidence based or 
validated.
THE PRACTALL GUIDELINES
The PRACTALL guidelines
7 for the management of childhood 
asthma were developed recognising that the evidence base on 
specific aspects of paediatric asthma management, including 
therapeutic strategies is severely limited, particularly for chil-
dren under 5 years. The European Academy of Allergy and Clin-
ical Immunology and the American Academy of Allergy there-
fore nominated expert teams to find a consensus to serve as a 
guideline for practice in Europe as well as in North America. 
Thus these guidelines were not intended for global usage (e.g., 
in underdeveloped countries).
In these guidelines 4 patterns of asthma are proposed:
1. Transient wheezing: in the first 2-3 years
2.   Non-atopic wheezing: triggered by viral infections and re-
mitting later in childhood
3.   Persistent asthma: with atopy, eosinophilia, food allergy, 
positive parental history and high indoor allergen exposure
4.   Severe intermittent wheezing: infrequent episodes with 
minimal morbidity between episodes but with atopic char-
acteristics present.
Step up if
needed
(first check 
adherence,
inhaler technique, 
and environmental 
control)
Step down if 
possible
(and asthma is
well controlled
at least 3 months)
Intermittent
asthma
Persistent asthma: daily medication
Consult with asthma specialist if step 3 care or higher is required.
Consider consultation at step 2.
Quick-relief medication for all patients
•    SABA as needed for symptoms, intensity of treatment depends on severity of symptoms
•    With viral respiratory infection: SABA q 4-6 hr up to 24 hr (longer with physician consult). Consider short course of oral systemic 
corticosteroids if exacerbation is severe or patient has history of previous exacerbations.
•    Caution: Frequent use of SABA may indicate the need to step up treatment. See text for recommendations on initiating daily 
long-term-control therapy.
Step 1
Preferred:
SABA PRN
Step 2
Preferred:
Low-dose ICS
Alternative:
Cromolyn or 
Montelukast
Step 3
Preferred:
Medium-dose
ICS
Step 4
Preferred:
Medium-dose
ICS + either
LABA or
Montelukast
Step 5
Preferred:
High-dose
ICS + either
LABA or
Montelukast
Step 6
Preferred:
High-dose
ICS + either
LABA or
Montelukast
Oral systemic
corticosteroids
Patient education and environmental control at each step
Assess
control
Fig. 1.  Stepwise approach for managing asthma in children 0-4 yr of age.
Alphabetical order is used when more than one treatment option is listed within either preferred or alternative therapy.
ICS, inhaled corticosteroid; LABA, inhaled long-acting b2-agonist; SABA, inhaled short-acting b2-agonist.
• The stepwise approach is meant to assist, not replace, the clinical decision making required to meet individual patient needs.
• If alternative treatment is used and response is inadequate, discontinue it and use the preferred treatment before stepping up.
•   If clear benefit is not observed within 4-6 wk and patient/family medication technique and adherence are satisfactory, consider adjusting therapy or alternative di-
agnosis.
•   Studies on children 0-4 yr of age are limited. Step 2 preferred therapy is based on Evidence A. All other recommendations are based on expert opinion and extrap-
olation from studies in older children.Allergy Asthma Immunol Res. 2010 January;2(1):1-13.  doi: 10.4168/aair.2010.2.1.1
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The PRACTALL guidelines are fairly easy for the clinician to 
follow. A key point to making a firm diagnosis of asthma in in-
fants 0-2 years is the persistence of symptoms. In children 3-5 
years persistence versus intermittent wheezing is more sugges-
tive of asthma, whereas in children 6-12 years, allergen induced 
symptoms and seasonality suggest a diagnosis of asthma.
These guidelines stress the importance of the history (family 
history, previous or current eczema, exacerbation rate, identifi-
able triggers [e.g., exercise]) examination (evidence of atopy 
such as drug, skin, dermatitis, conjunctivitis and rhinitis). Tests 
such as skin prick tests and Immunocap RASTs are considered 
important when assessing all children with recurrent wheeze 
and lung function and peak flow reversibility should be con-
ducted in those old enough to perform such tests.
The guidelines encourage the clinician to decide whether epi-
sodes are precipitated mainly by colds: “virus induced asthma” , 
exercise: “exercise induced asthma” , allergens “allergen induced 
asthma” or different aetiologies (including irritant exposure). 
Using such an approach, “asthma phenotypes” are identified.
In order to obtain a confident diagnosis of atopy, the history 
should focus on frequency of symptoms (including wheeze, 
nocturnal cough, exercise induced wheeze and persistence of 
cough with colds) as well as more indirect assessments such as 
fatigue, poor school performance, avoidance of normal play 
and specific triggers (e.g., exercise). The clinical examination 
should look for evidence of eczema, dry skin, allergic shiners, 
irritated conjunctive and persistent oedema of the nasal muco-
sa, allergic salute and allergic crease on the bridge of the nose.
Recommendations include avoidance of exposure to tobac-
co-smoke, a balanced diet, avoidance of obesity and encour-
agement of exercise. Allergen avoidance is recommended 
when there is sensitisation and a clear association between al-
lergen exposure and symptoms. The PRACTALL guidelines also 
provide a treatment algorithm for the treatment of asthma in 
Components of severity
Classification of asthma severity (0-4 yr of age)
Intermittent
Persistent
Mild Moderate Severe
Impairment
Symptoms ≤2 days/wk >2 days/wk but not daily Daily Throughout the day
Night-time awakenings 0 1-2x/mo 3-4x/mo >1x/wk
Short-acting b2-agonist use for 
symptom control (not prevention of EIB)
≤2 days/wk >2 days/wk but not daily Daily Several times per day
Interference with normal activity None Minor limitation Some limitation Extremely limited
Risk
Exacerbations requiring oral systemic 
corticosteroids
0-1/yr
≥2 exacerbations in 6 mo requiring oral systemic corticosteroids, 
or ≥4 wheezing episodes/1 yr lasting >1 day AND risk factors for persistent asthma
Consider severity and interval since last exacerbation.
Frequency and severity may fluctuate over time.
Exacerbations of any severity may occur in patients in any severity category.
Recommended step for initiating therapy
Step 1 Step 2
Step 3 and consider short course 
of oral systemic corticosteroids
In 2-6 wk, depending on severity, evaluate level of asthma control that is achieved.
If no clear benefit is observed in 4-6 wk, consider adjusting therapy or alternative diagnoses.
Fig. 2.  Classifying asthma severity and initiating treatment in children 0-4 yr of age. Assessing severity and initiating therapy in children who are not currently tak-
ing long-term control medication.
EIB, exercise-induced bronchospasm.
• The stepwise approach is meant to assist, not replace, the clinical decision making required to meet individual patient needs.
• Level of severity is determined by both impairment and risk. Assess impairment domain by patient’s/caregiver’s recall of previous 2-4 wk. Symptom assessment 
for longer periods should reflect a global assessment such as inquiring whether the patient’s asthma is better or worse since the last visit. Assign severity to the 
most severe category in which any feature occurs.
• At present, there are inadequate data to correspond frequencies of exacerbations with different levels of asthma severity. For treatment purposes, patients who 
had ≥2 exacerbations requiring oral systemic corticosteroids in the past 6 months, or ≥4 wheezing episodes in the past year, and who have risk factors for persis-
tent asthma may be considered the same as patients who have persistent asthma, even in the absence of impairment levels consistent with persistent asthma.Allergy Asthma Immunol Res. 2010 January;2(1):1-13.  doi: 10.4168/aair.2010.2.1.1
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children over 2 years of age.
7
The treatment algorithm is a step-up and step-down ap-
proach, but is not graded by level of impairment or risk as is 
suggested in the EP3 guidelines. For acute attacks, Ipratropium 
bromide combined with b2 agonists may result in favourable 
outcomes in children.
22 Inhaled corticosteroids are recom-
mended as a first line treatment for persistent asthma with leu-
kotriene receptor antagonists as an alternative.
23
Evidence for the anti-inflammatory effects of Montelukast on 
nitric oxide exhalation is cited
24 and its usefulness as add on 
treatment to inhaled corticosteroids
25 justifies its place in step 
up treatment. Because efficacy of LABA in the management of 
young children is still unclear
26 and suggestions that children 
using LABA’s regularly
27 may have an increased risk of exacerba-
tions and hospitalisations, the PRACTALL guidelines only rec-
ommend their use in severe asthmatics unresponsive to inhaled 
corticosteroids at high doses, or in those in whom the addition 
of LTRA’s have not improved the patient’s symptoms. LABA’s 
should never be used without concomitant inhaled corticoste-
roids.
The PRACTALL guidelines also address asthma treatment in 
children 0-2 years. Intermittent b2 agonists are the first choice 
and LTRA’s are recommended for long or short term treatment 
of viral wheezing. Nebulised or MDI plus spacer delivered in-
Components of control
Classification of asthma control (0-4 yr of age)
Well controlled Not well controlled Very poorly controlled
Impairment
Symptoms >2 days/wk ≥2 days/wk Throughout the day
Night-time awakenings ≤1x/mo >1x/mo >1x/wk
Interference with normal 
activity
None Some limitation Extremely limited
Short-acting b2-agonist 
use for symptom control 
(not prevention of EIB)
≤2 days/wk >2 days/wk Several times per day
Risk
Exacerbations requiring oral 
systemic corticosteroids
0-1/yr 2-3/yr >3/yr
Treatment-related adverse 
effects
Medication side effects can vary in intensity from none to very troublesome and worrisome.
The level of intensity does not correlate to specific levels of control but should be considered 
in the overall assessment of risk.
Recommended action for treatment
•   Maintain current treatment
•   Regular follow up every 
1-6 mo
•   Consider step down if well 
controlled for at least 3 mo
•   Step up (1 step) and
•   Re-evaluate in 2-6 wk
•   If no clear benefit in 4-6 wk, consider 
alternative diagnoses or adjusting 
therapy
•   For side effects, consider alternative 
treatment options
•   Consider short course of oral systemic 
corticosteroids
•   Step up (1-2 steps), and
•   Re-evaluate in 2 wk
•   If no clear benefit in 4-6 wk, consider 
alternative diagnoses or adjusting therapy
•   For side effects, consider alternative 
treatment options
Fig. 3.  Assessing asthma control and adjusting therapy in children 0-4 yr of age.
EIB, exercise-induced bronchospasm.
• The stepwise approach is meant to assist, not replace, the clinical decision making required to meet individual patient needs.
• The level of control is based on the most severe impairment or risk category. Assess impairment domain by caregiver’s recall of previous 2-4 wk. Symptom as-
sessment for longer periods should reflect a global assessment such as inquiring whether the patient’s asthma is better or worse since the last visit.
• At present, there are inadequate data to correspond frequencies of exacerbations with different levels of asthma control. In general, more frequent and intense 
exacerbations (e.g., requiring urgent, unscheduled care, hospitalization, or ICU admission) indicate poorer disease control. For treatment purposes, patients who 
had ≥2 exacerbations requiring oral systemic corticosteroids in the past year may be considered the same as patients who have not-well-controlled asthma, even 
in the absence of impairment levels consistent with not-well-controlled asthma.
• Before step up in therapy: Review adherence to medications, inhaler technique, and environmental control. If alternative treatment option was used in a step, dis-
continue it and use preferred treatment for that step.Allergy Asthma Immunol Res. 2010 January;2(1):1-13.  doi: 10.4168/aair.2010.2.1.1
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haled corticosteroids are recommended for persistent asthma, 
especially when severe episodes requiring frequent oral corti-
costeroids have occurred. Evidence of atopy should lower the 
threshold for inhaled corticosteroid therapy, which should be 
first line in such cases. There are very few studies of the efficacy 
and safety of allergen immunotherapy for asthmatics under the 
age of 5 years.
Sublingual immunotherapy (SLIT) may be a safe and effective 
alternative to subcutaneous injections in children with asthma
28 
and the effects may be long lasting,
29 but immunotherapy is not 
recommended when asthma is unstable. Patients should have 
few, if any, symptoms and a FEV1 of at least 80% of predicted val-
ue. Age is not an absolute contraindication and therapy can be 
given from 3 years of age, with caution by well trained staff in 
specialist centres.
Children under 5 years should be given practical instructions 
on inhaler use while their parents require training in inhaler 
devices and strategies for managing episodes. They should be 
provided with theoretical and practical education including a 
written action plan. Asthma education is an integral part of 
asthma management and must be offered to all parties in-
volved. The asthma quiz for kids
30 and the paediatric asthma 
control tests
31 are patient based tools for identifying children 
with uncontrolled asthma.
THE ERS TASK FORCE GUIDELINES
These guidelines were developed as evidence based guide-
lines while recognising that there is limited evidence available 
for the treatment of wheezing disorders in preschool children. 
The cumulative prevalence of wheeze is almost 50% by the time 
children are 6 years old.
32 It is proposed that given the multifac-
torial nature of all wheezing disorders in childhood, the clinical 
phenotypes described in the literature are extremes of a broad 
spectrum of wheezing disorders.
33 These guidelines utilised the 
Cochrane Library, Pubmed and EMBASE to search for evi-
dence based treatments and graded the evidence into high, 
moderate or low grade evidence based on study design and 
quality and also applied the GRADE methodology.
34
They concluded that almost all of the evidence available was 
of low quality. In quoting the GINA definition that asthma is a 
syndrome with a highly variable clinical spectrum character-
ised by airway inflammation,
35 they point out that inflamma-
tion has been poorly studied in preschool children and may be 
absent in very young children who wheeze. Thus, the majority 
of the task force agreed not to use the term “asthma” to describe 
preschool wheezing since there is “insufficient evidence show-
ing that the pathophysiology of preschool wheezing is similar 
to that of asthma in older children or adults” .
It is believed that specific combinations of genetic and envi-
ronmental factors determine the patient’s phenotype, but that 
in clinical practice most of these factors are as yet unknown. 
Furthermore the guidelines stress that the descriptions of 
wheeze used in epidemiological studies (transient versus per-
sistent wheeze) can only be applied retrospectively.
19 It was 
thus suggested that definitions of temporal patterns of a wheeze 
would be more useful to clinicians, than retrospective defini-
tions of wheeze which would be more useful for epidemiologi-
cal studies.
A temporal pattern of wheeze is thus suggested. Wheeze may 
be an “episodic viral wheeze” , with the child being well between 
episodes. These episodes are caused by rhinovirus, respiratory 
syncytial virus, human meta pneumo virus, para influenza vi-
rus and adenovirus.
Whether or not the initial episode is classified as “bronchiol-
itis” is irrelevant. Episodic viral wheeze disappears by the age of 
six years, but may continue into school age or change into 
“multiple-trigger wheeze” . “Multiple-trigger wheeze” describes 
children who also respond with wheezing to other triggers. 
These include tobacco, crying, laughter or exercise.
36 Many be-
lieve that “multiple-trigger wheeze” reflects chronic allergic air-
way disease and could be classified as asthma. This classifica-
tion differs from the retrospective epidemiological classifica-
tion of wheezing reported from the Tucson birth cohort
19 of 
“transient” and “persistent wheezing” . Children with transient 
wheezing, wheezed during the first 3 years of life and do not 
have a personal history of eczema or a family history of asthma. 
The group of “late onset wheezers” who started wheezing after 
3 years often had associated maternal asthma, male sex and a 
history of rhinitis.
The diagnosis of wheezing is made by history taking alone and 
investigations are justified when symptoms are present from 
birth, airway obstruction is abnormally severe and recovery is 
slow, or incomplete, or associated with repeated admissions.
Sensitisation to hen’s egg at the age of 1 year is a reasonable 
marker for allergic sensitisation to aeroallergens at age 3 years 
with a specificity of >90% and sensitivity of 30%.
37
There appear to be no studies supporting the usefulness of 
pulmonary function tests in children with non-specific symp-
toms, or in distinguishing between episodic and multiple trig-
ger wheeze, but a bronchodilator response in young children 
may assist in discriminating common wheezing disorders from 
other conditions. Reference values for FeNo are only available 
for children over 4 years.
38
Biopsy evidence of inflammation of the airways in young chil-
dren is scarce and the only consistent biopsy finding in wheezy 
children is thickening of the basement membrane,
39 but not in 
infants at median age of 12 months, whereas a study done at 
mean age 29 months in wheezy children
40 reported eosinophilic 
airway inflammation and reticular basement membrane thick-
ening, implying an age window during when “inflammation” 
develops.
Treatment guidelines stress the importance of allergen avoid-
ance but it is unclear whether the required reduction in allergen Allergy Asthma Immunol Res. 2010 January;2(1):1-13.  doi: 10.4168/aair.2010.2.1.1
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exposure can be achieved in normal life and there are no stud-
ies or allergen avoidance in preschool children with wheeze.
41 
Studies on the effectiveness of parental education are disap-
pointing.
42
Treatment guidelines of the ERS task force recommend in-
haled b2 agonists as the most effective bronchodilators available; 
suggesting that single isomer R-albuterol is preferable. There are 
no published randomised placebo controlled trials in preschool 
children on the addition of long acting b2 agonists to inhaled 
corticosteroids. Inhaled corticosteroids are effective for symp-
tom control, reduction of exacerbations, lung function and air-
way responsiveness in children with multiple-trigger wheeze.
43
Doses recommended in preschool children up to 400 µg Be-
clomethazone equivalent may be used with metered dose in-
haler plus a spacer, without benefit from higher doses. Those 
with a positive family history, over 2 years and frequent symp-
toms show the best response to inhaled steroids. However one 
study using inhaled Fluticazone to wheezy infants showed no 
improvement in lung function.
44 It is suggested that after a trial 
of 3 months of inhaled corticosteroids, treatment should be 
withdrawn in those who become almost completely free of 
wheeze to assess the need for ongoing therapy.
For episodic viral wheeze the clinical benefits of inhaled corti-
costeroids are controversial and maintenance treatment up to 
400 µg/day does not reduce the severity or frequency of attacks 
in these children. Nasal steroids have not been demonstrated 
to be of benefit in preschool children with recurrent wheeze 
with allergic rhinitis. Furthermore there is no evidence that par-
ent initiated oral steroids are associated with benefit, in terms 
of hospital admissions, symptom scores, or bronchodilator use.
A study of Montelukast in 689 young children with multiple-
trigger wheeze achieved an improvement in symptom and a 
30% reduction in exacerbations.
23 Cromones and Xanthenes 
are not recommended and neither is allergen immunotherapy 
outside the setting of a randomised controlled trial.
THE NEW GINA GUIDELINES
A comprehensive strategy for asthma management and pre-
vention in children 5 years and younger has recently been pub-
lished.
9 It addresses risk factors associated with the develop-
ment of asthma, the diagnosis of asthma and management and 
pharmacological treatment (education, control, pharmacother-
apy and the management of acute exacerbations). These guide-
lines are evidence based using Categories A-D in which Cate-
gory A is derived from a rich body of data of randomised con-
trolled trials, Category B from a limited body of controlled trial 
data, post hoc analysis or meta analysis of RCT, Category C for 
non-randomised or observational studies and Category D for 
panel consensus judgment.
For risk factors of asthma the guidelines recognise that there 
is mixed evidence for house dust mite avoidance and no evi-
dence that anti-house dust measures prevent the onset of asth-
ma. Unless the child is sensitised to a pet species, there is insuf-
ficient data to recommend for or against the presence of a pet 
in the house. Sensitization to cockroaches is associated with an 
increased risk of developing asthma
45 and sensitization to Al-
ternaria is a risk factor for more severe asthma.
46 There is no ev-
idence that diet in pregnancy or breast feeding or probiotics in-
fluences the development of asthma, but some evidence that a 
farming environment may be protective.
A diagnosis of asthma should be considered when a young 
child presents a symptom pattern of wheeze/cough occurring 
recurrently, during sleep, with activity, laughing or crying in the 
presence of a positive family history and evidence of allergic 
sensitisation. Although no tests diagnose asthma with certainty 
in young children, a therapeutic trial with short acting bron-
chodilators and inhaled glucocorticosteroids for at least 8-12 
weeks may provide some guidance as to the presence of asth-
ma (Evidence D). Lung function, bronchial challenge and other 
physiological tests do not have a major role in the diagnosis of 
asthma in children 5 years and younger. To aid early identifica-
tion of asthma in the clinical setting, a number of risk profiles 
and predictive assessments have been published. The Asthma 
Predictive Index (API)
47 based on the Tuscan study showed that 
a child with a positive API has a 4-10 fold greater chance of de-
veloping asthma between ages 6 and 13 while 95% of children 
with a negative API remained free of asthma (Evidence C).
For children under 5, asthma management plans based on 
the level of respiratory symptoms are just as effective as plans 
based on self monitoring of lung function (Evidence B).
48 The 
relationship between “current control” and “future risk” de-
scribed in the NAEPP guidelines
6 have not yet been carefully 
studied in small children. The importance of good daily asthma 
control is stressed. The guidelines warn against excessive or 
prolonged unnecessary use of inhaled, or systemic corticoste-
roids, since many children with wheezing go into remission. No 
objective measures to assess clinical control have been validat-
ed in children younger than 4 years. It appears that “asthma” is 
rare in the transient wheeze groups, but there are other pheno-
types.
Inhaled glucocorticosteroids are effective in the management 
of asthma in young children (Evidence A), but do not induce a 
remission. Low doses have not been associated with any clini-
cally serious adverse systemic effects.
Table 1 lists the low doses which have not been associated 
with clinically adverse effects in trials including measures of 
safety. Table 2 presents the GINA management approach based 
on asthma control for children 5 years and younger.
Anti leukotrienes improve asthma outcomes in young chil-
dren (Evidence A), however the role of leukotrienes as add on 
therapy in children under 5 years whose asthma is uncon-
trolled on inhaled glucocorticosteroids has not yet been specif-
ically evaluated. Leukotriene receptor antagonists are safe.Allergy Asthma Immunol Res. 2010 January;2(1):1-13.  doi: 10.4168/aair.2010.2.1.1
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Long acting bronchodilators are not recommended for chil-
dren under 5 years (Evidence D) and cromolyn cannot be rec-
ommended (Evidence A). Suggested levels of control are pro-
vided in Table 3 for children 5 years and younger with asthma.
The treatment of intermittent wheezing remains controversial 
where a diagnosis of asthma seems unlikely. Evidence for effi-
cacy of short term controllers (e.g., inhaled glucocorticoste-
roids, leukotriene modifiers and oral glucocorticosteroids) is 
lacking. The initial treatment is a dose of rapidly acting inhaled 
b2 agonist every 4-6 hours as needed for a day or more until 
symptoms disappear (Evidence A). Regular controller treat-
ment may be indicated in a child with less frequent but more 
severe episodes of viral induced wheeze (Evidence D). The new 
GINA guidelines also provide detailed management plans for 
acute exacerbations.
CONCLUSIONS
All the recent guidelines have stressed the difficulties in mak-
ing a firm diagnosis of asthma in children under 5 and several 
wheezy phenotypes have been identified. Each of the guide-
lines provides a unique perspective and important insights into 
the problems facing clinicians treating young children with 
asthma and there are a number of recommendations which are 
clear and are repeated in each of the guidelines.
However, following guidelines depend on factors within the 
guidelines themselves, social-cultural context of the strategies 
used to spread them and organizational, economic and political 
context for the implementation of guideline strategies.
49 Knowl-
edge, attitude, skills, experiences, beliefs and values play a fun-
damental role both for the physician, the parent and the patient. 
Lack of consensus among different new guidelines can be a ma-
jor obstacle to doctors adopting a particular guideline and com-
plex guidelines are not practical for busy doctors to follow.
Lack of familiarity with guidelines is a common problem and 
it has been estimated that over 10% of doctors ignore the exis-
tence of 78% of available guidelines.
49 Guidelines may not be 
followed if they are considered to be based on “opinion” , poor 
evidence, or do not consider patients values and preferences.
Thus for the under 5’s we have a lot of information through ex-
tensive reviews of the available literature on studies of asthma 
aetiology, phenotypes, natural history and pharmacotherapy 
which is consolidated in the available guidelines.
In the future new guidelines are expected to be published us-
ing the GRADE system (Grading of Recommendations, Assess-
ment, Development and Evaluation) whose activity is endorsed 
by the WHO
34 and an attempt has been made to include as-
pects of the GRADE recommendation in the ERS guidelines.
8
This new method will not only assess the quality of the evi-
dence across studies for each important outcome but the bal-
ance between benefits, harm and strengths of recommenda-
tions, bringing scientific evidence near to real life situations 
which will make guidelines easier to apply.
The available guidelines do not adequately address the man-
agement of asthma or wheezing phenotypes for children under 
the age of 5 in the underdeveloped world where there is a lack 
of resources, but also because there is an absence of studies on 
asthma management in practice in the under 5’s in these re-
gions.
It would be prudent for regions and countries to consider all 
the available guidelines and to adapt then so that they are un-
derstandable in regional contexts and that the recommenda-
tions are in line with available resources in a particular region 
Table 1.  Low daily doses* of inhaled glucocorticosteroids for children 5 yr and 
younger
Drug Low daily dose (µg)
Beclomethasone dipropionate 100
Budesonide MDI + spacer
Budesonide nebulized 200
500
†Ciclesonide NS
Fluticasone propionate 100
†Mometasone furoate NS
†Triamcinolone acetonide NS
*A low dose is defined as the dose which has not been associated with clini-
cally adverse effects in trials including measures of safety. This is not a table of 
clinical equivalence.
†NS = not studied in this age group.
Table 2.  Asthma management approach based on control for children 5 yr and 
younger
Asthma education
Environmental control
As needed rapid-acting b2-agonists
Controlled on as
needed rapid-acting
b2-agonists
Partly controlled on as 
needed rapid-acting
b2-agonists
Uncontrolled or only 
partly controlled
on low-dose inhaled 
glucocorticosteroid*
y y y
Controller options
Continue as needed 
rapid-acting b2-agonists
Low-dose inhaled 
glucocorticosteroid
Double low-dose inhaled 
glucocorticosteroid
Leukotriene modifier
Low-dose inhaled 
glucocorticosteroid plus 
leukotriene modifier
*Oral glucocorticosteroids should be used only for treatment of acute severe ex-
acerbations of asthma. Shaded boxes represent the preferred treatment options.Allergy Asthma Immunol Res. 2010 January;2(1):1-13.  doi: 10.4168/aair.2010.2.1.1
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to facilitate their implementation and thus improve the man-
agement of asthma in young children around the world.
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